BSX vs. PEN: Boston Scientific vs. Penumbra Stock Comparison

Company Profile

Boston Scientific (BSX) and Penumbra (PEN) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Boston Scientific (BSX) is heavily traded at around 19.73M shares per day, whereas Penumbra (PEN) sees a more moderate 348.64K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Boston Scientific (BSX) at 14.12% and Penumbra (PEN) at 10.67% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

For every dollar of sales, both Boston Scientific (BSX) at 16.62% and Penumbra (PEN) at 10.06% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Boston Scientific (BSX) at 19.05% operates in the top operating margin quartile, ahead of Penumbra (PEN) at 12.37%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Boston Scientific (BSX) at 19.87% and Penumbra (PEN) at 17.50% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both companies show strong earnings momentum, but Penumbra (PEN) at 1,155.56% is the standout with EPS growth above its industry range; Boston Scientific (BSX) at 55.20% also sits in the top quartile.

Growth Metrics

Financial Strength

Penumbra (PEN) at 5.89 carries current ratio above its industry’s typical mid-range, while Boston Scientific (BSX) at 1.37 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Penumbra (PEN) at 0.13 keeps leverage in the lower industry quartile, while Boston Scientific (BSX) at 0.46 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Boston Scientific (BSX) nor Penumbra (PEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Boston Scientific (BSX) nor Penumbra (PEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Boston Scientific (BSX) at 18.04 sits in the cheaper P/E ratio quartile, while Penumbra (PEN) at 80.41 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

Boston Scientific (BSX) at 2.94 is priced about in line with its industry on P/S ratio, while Penumbra (PEN) at 8.06 sits in the pricier quartile — PEN costs more per dollar of sales.

Boston Scientific (BSX) at 2.42 is valued about in line with its industry on P/B ratio, while Penumbra (PEN) at 7.95 carries an above-peer premium to book — PEN is pricier on assets.

Valuation Metrics